3-benzyl-N-(methanesulfonyloxy)succinimide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 129431 |
| CHEMBL ID | 11739 |
| SCHEMBL ID | 10402210 |
| MeSH ID | M0145606 |
| Synonym |
|---|
| bmsos |
| CHEMBL11739 |
| (3-benzyl-2,5-dioxopyrrolidin-1-yl) methanesulfonate |
| 2,5-pyrrolidinedione, 1-((methylsulfonyl)oxy)-3-(phenylmethyl)-, (+-)- |
| (+-)-1-((methylsulfonyl)oxy)-3-(phenylmethyl)-2,5-pyrrolidinedione |
| 3-benzyl-n-(methanesulfonyloxy)succinimide |
| 3-benzyl-n-((methylsulfonyl)oxy)succinimide |
| 106847-87-4 |
| SCHEMBL10402210 |
| 3-benzyl-1-[(methanesulfonyl)oxy]pyrrolidine-2,5-dione |
| DTXSID80910133 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID99444 | Catalytic rate constant (Kobs/[I]) against human leukocyte elastase was determined | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | Inhibition of human leukocyte elastase by derivatives of N-hydroxysuccinimide. A structure-activity-relationship study. |
| AID165350 | Evaluated for the inhibition of Human leukocyte Proteinase 3 (PR-3); Inactive | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Inhibitors of human leukocyte proteinase-3. |
| AID66999 | Evaluated for the inhibition of Human leukocyte elastase | 1990 | Journal of medicinal chemistry, Apr, Volume: 33, Issue:4 | Inhibitors of human leukocyte proteinase-3. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||